Intelligence Report · ~12 min read

Merck Intelligence Report

Generated from 125 signals · 14 evidence sources

Type

Company Intelligence Report

Generated

Jul 21, 2026

Confidence

Moderate Confidence · 68%

Evidence

687 items

Sources

215

Executive Summary

Synthesized assessment from linked signals, findings, and evidence relationships.

Merck maintains an active intelligence profile across Oncology, KRAS Inhibitor, Cardiology, Pulmonary Arterial Hypertension, Gastroenterology. 125 signals are linked with 14 investigate-priority items requiring leadership attention. Competitive pressure is high with high portfolio impact. Evidence coverage stands at 68% across 14 tracked sources. Highest-priority development: FDA Accepts Supplement for Trodelvy (Sacituzumab Govitecan-Hziy). Portfolio development. FDA Accepts Supplement for Trodelvy (Sacituzumab Govitecan-Hziy) is an owned Merck portfolio development in Oncology · Antibody-Drug Conjugate.

Key Developments

Material intelligence events ranked by strategic relevance.

investigateJun 17, 2026
Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Infectious Disease · Respiratory Syncytial Virus (RSV) · opportunity score 449
View detail
investigateJun 22, 2026
FDA approves belzutifan with pembrolizumab for renal cell carcinoma treatment
Oncology · Renal Cell Carcinoma · opportunity score 445
View detail
investigateJun 16, 2026
Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir
Infectious Disease · HIV · opportunity score 444
View detail
investigateJun 16, 2026
Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC
Oncology · NSCLC · opportunity score 444
View detail
investigateJul 18, 2026
Merck's LIPFENDRA Approved as First Oral PCSK9 Inhibitor for Hypercholesterolemia
Cardiology · Hypercholesterolemia · opportunity score 439
View detail
investigateJun 17, 2026
FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX in MIBC Treatment
Oncology · Bladder Cancer · opportunity score 439
View detail
investigateJun 16, 2026
FDA Grants Breakthrough Therapy Designation for Calderasib in KRAS G12C-Mutant NSCLC
Oncology · KRAS G12C Inhibitor · opportunity score 439
View detail
investigateJun 1, 2026
Breztri Gains US Approval as First Triple Therapy for Asthma
Respiratory · Asthma · opportunity score 439
View detail
investigateJun 17, 2026
Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma
Oncology · Melanoma · opportunity score 438
View detail
investigateJun 17, 2026
Merck and Eisai's LITESPARK-012 Trial Fails to Meet Primary Endpoints in RCC
Oncology · Renal Cell Carcinoma · opportunity score 438
View detail
investigateJun 16, 2026
Merck Reports Promising Long-Term Data for KEYTRUDA and Intismeran in Oncology at ASCO 2026
Oncology · Immunotherapy · opportunity score 438
View detail
investigateJun 16, 2026
5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%
Oncology · Melanoma · opportunity score 438
View detail

Strategic Implications

Portfolio and competitive decisions informed by this intelligence profile.

Opportunity score 54662 with buyer quality 10 (Enterprise). Competitive pressure: High. Portfolio impact: High. 14 investigate-priority signals warrant near-term portfolio review. Competitiva linkage surfaces 8 competitive findings requiring monitoring.

Supporting Evidence

Evidence-backed items with source attribution and confidence disclosure.

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patient
Moderate Confidence · 80%
Elevated competitive pressure
Source: Merck, Competitiva
View evidence
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patient
Moderate Confidence · 70%
Elevated competitive pressure
Source: Merck, Competitiva
View evidence
FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patient
Low Confidence · 59%
Elevated competitive pressure
Source: Merck, Competitiva
View evidence
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung
High Confidence · 91%
Elevated competitive pressure
Source: Merck, Competitiva
View evidence
FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung
Moderate Confidence · 68%
Elevated competitive pressure
Source: Merck, Competitiva
View evidence
European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season
Moderate Confidence · 77%
Elevated competitive pressure
Source: Merck, Competitiva
View evidence
5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%
High Confidence · 95%
Potential competitive pressure
Source: Merck, Competitiva
View evidence
5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%
High Confidence · 95%
Potential competitive pressure
Source: Humanexa Signals, Competitiva
View evidence
FDA Accepts Supplement for Trodelvy (Sacituzumab Govitecan-Hziy)
Low Confidence · 0%
FDA approval
Source: Merck, FDA, Portfolio
View evidence
FDA Accepts Supplement for Gleevec (Imatinib Mesylate) by Novartis
Low Confidence · 0%
FDA approval
Source: Humanexa Signals, FDA, Portfolio
View evidence
Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer
Low Confidence · 0%
FDA approval
Source: Humanexa Signals, ClinicalTrials.gov, Portfolio
View evidence
FDA Accepts Supplemental Application for Emgality (Galcanezumab) by Eli Lilly
Low Confidence · 0%
FDA approval
Source: Merck, FDA, Portfolio
View evidence
Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer
Low Confidence · 0%
FDA approval
Source: Merck, ClinicalTrials.gov, Portfolio
View evidence
RAPTOR Trial Evaluates Radiation Therapy with Atezolizumab in Extensive Stage Small Cell Lung Cancer
Low Confidence · 0%
FDA approval
Source: Humanexa Signals, ClinicalTrials.gov, Portfolio
View evidence
RAPTOR Trial Evaluates Radiation Therapy with Atezolizumab in Extensive Stage Small Cell Lung Cancer
Low Confidence · 0%
FDA approval
Source: Merck, ClinicalTrials.gov, Portfolio
View evidence
FDA Accepts Supplemental Application for Emgality (Galcanezumab)
Low Confidence · 0%
FDA approval
Source: Merck, FDA, Portfolio
View evidence

Related Intelligence

Deep links to signals, insights, companies, and assets in the Humanexa graph.

Signals

Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants
Infectious Disease · Respiratory Syncytial Virus (RSV)
FDA approves belzutifan with pembrolizumab for renal cell carcinoma treatment
Oncology · Renal Cell Carcinoma
Merck's MK-2214 Trial Aims to Slow Tau Spread in Early Alzheimer's Disease
Neurology · Alzheimer's Disease
Intismeran Autogene Plus Pembrolizumab Trial for NSCLC Initiated by Merck and Moderna
Oncology · Non-small Cell Lung Cancer
Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir
Infectious Disease · HIV
Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC
Oncology · NSCLC
FDA grants Priority Review for Roche’s Tecentriq in stage III colon cancer
Oncology · Immunotherapy
Merck's Sacituzumab Tirumotecan Trial Targets High-Risk Breast Cancer
Oncology · Breast Cancer

Executive Summary

Key Developments

Merck's ENFLONSIA Approved in EU for RSV Prevention in Infants

FDA approves belzutifan with pembrolizumab for renal cell carcinoma treatment

Gilead and Merck Report Positive Phase 3 Results for Once-Weekly HIV Treatment Islatravir/Lenacapavir

Merck and Gilead Discontinue Phase 3 Study of Trodelvy and KEYTRUDA in NSCLC

Merck's LIPFENDRA Approved as First Oral PCSK9 Inhibitor for Hypercholesterolemia

FDA Grants Priority Review for KEYTRUDA and KEYTRUDA QLEX in MIBC Treatment

FDA Grants Breakthrough Therapy Designation for Calderasib in KRAS G12C-Mutant NSCLC

Breztri Gains US Approval as First Triple Therapy for Asthma

Lactylation-related biomarker predicts prognosis and therapy response in cutaneous melanoma

Merck and Eisai's LITESPARK-012 Trial Fails to Meet Primary Endpoints in RCC

Merck Reports Promising Long-Term Data for KEYTRUDA and Intismeran in Oncology at ASCO 2026

5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%

Strategic Implications

Supporting Evidence

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patient

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patient

FDA Grants Priority Review for KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Each with Padcev® (enfortumab vedotin-ejfv), for Cisplatin-Eligible Patient

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung

FDA Grants Breakthrough Therapy Designation for Calderasib (MK-1084), an Investigational KRAS G12C Inhibitor, for Certain Patients with Newly Diagnosed Metastatic KRAS G12C-Mutant Non-Small Cell Lung

European Commission Approves Merck’s ENFLONSIA™ (clesrovimab) for the Prevention of Respiratory Syncytial Virus (RSV) Lower Respiratory Tract Disease in Infants During Their First RSV Season

5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%

5-Year Data Shows Intismeran Autogene + KEYTRUDA Reduces Melanoma Recurrence Risk by 49%

FDA Accepts Supplement for Trodelvy (Sacituzumab Govitecan-Hziy)

FDA Accepts Supplement for Gleevec (Imatinib Mesylate) by Novartis

Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer

FDA Accepts Supplemental Application for Emgality (Galcanezumab) by Eli Lilly

Phase III Trial of Osimertinib and Bevacizumab in EGFR-Mutant Lung Cancer

RAPTOR Trial Evaluates Radiation Therapy with Atezolizumab in Extensive Stage Small Cell Lung Cancer

RAPTOR Trial Evaluates Radiation Therapy with Atezolizumab in Extensive Stage Small Cell Lung Cancer

FDA Accepts Supplemental Application for Emgality (Galcanezumab)

Related Intelligence

Signals